Coeptis Therapeutics Holdings Inc
COEP11.270USD
+0.660+6.22%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
58.13MCap. mercado
PérdidaP/E TTM
Más Datos de Coeptis Therapeutics Holdings Inc Compañía
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical and technology company. The Company is focused on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio is highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. It is developing a universal, multi-antigen CAR technology licensed by the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and medical researchers at the Karolinska Institute. Its NexGenAI Affiliates Network platform offers AI-powered marketing software and robotic process automation capabilities. The Company’s subsidiaries include Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc. and SNAP Biosciences, Inc.
Información de Coeptis Therapeutics Holdings Inc
Símbolo de cotizaciónCOEP
Nombre de la empresaCoeptis Therapeutics Holdings Inc
Fecha de salida a bolsaDec 17, 2020
Director ejecutivoMehalick (David)
Número de empleados5
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 17
Dirección105 Bradford Road, Suite 420
CiudadWEXFORD
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal15090
Teléfono17249346467
Sitio Webhttps://coeptistx.com/
Símbolo de cotizaciónCOEP
Fecha de salida a bolsaDec 17, 2020
Director ejecutivoMehalick (David)
Ejecutivos de Coeptis Therapeutics Holdings Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. David Mehalick
Mr. David Mehalick
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
130.07K
--
Ms. Christine Sheehy
Ms. Christine Sheehy
Vice President - Compliance, Secretary
Vice President - Compliance, Secretary
50.53K
--
Mr. Daniel (Dan) Yerace
Mr. Daniel (Dan) Yerace
Vice President - Operations, Director
Vice President - Operations, Director
45.53K
--
Mr. Christopher Calise
Mr. Christopher Calise
Independent Director
Independent Director
--
--
Mr. Brian Cogley
Mr. Brian Cogley
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Tara Maria Desilva, Ph.D.
Dr. Tara Maria Desilva, Ph.D.
Independent Director
Independent Director
--
--
Mr. Philippe Deschamps
Mr. Philippe Deschamps
Independent Director
Independent Director
--
--
Mr. Christopher Cochran
Mr. Christopher Cochran
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. David Mehalick
Mr. David Mehalick
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
130.07K
--
Ms. Christine Sheehy
Ms. Christine Sheehy
Vice President - Compliance, Secretary
Vice President - Compliance, Secretary
50.53K
--
Mr. Daniel (Dan) Yerace
Mr. Daniel (Dan) Yerace
Vice President - Operations, Director
Vice President - Operations, Director
45.53K
--
Mr. Christopher Calise
Mr. Christopher Calise
Independent Director
Independent Director
--
--
Mr. Brian Cogley
Mr. Brian Cogley
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Tara Maria Desilva, Ph.D.
Dr. Tara Maria Desilva, Ph.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: jue., 20 de nov
Actualizado: jue., 20 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
5.89%
Calise (Chris)
5.43%
Mehalick (David)
2.26%
Armistice Capital LLC
1.64%
Sheehy (Christine Elise)
0.88%
Otro
83.90%
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
5.89%
Calise (Chris)
5.43%
Mehalick (David)
2.26%
Armistice Capital LLC
1.64%
Sheehy (Christine Elise)
0.88%
Otro
83.90%
Tipos de accionistas
Accionistas
Proporción
Individual Investor
9.42%
Investment Advisor
6.11%
Hedge Fund
1.97%
Investment Advisor/Hedge Fund
1.13%
Otro
81.37%
Participación institucional
Actualizado: lun., 8 de dic
Actualizado: lun., 8 de dic
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
36
241.64K
3.38%
--
2025Q3
37
241.64K
3.76%
+42.71K
2025Q2
35
198.94K
3.83%
+46.67K
2025Q1
35
152.27K
2.68%
+61.98K
2024Q4
37
107.84K
11.51%
-74.49K
2024Q3
50
182.34K
16.17%
+98.47K
2024Q2
52
83.87K
26.32%
-153.34K
2024Q1
74
237.20K
33.65%
-370.03K
2023Q4
75
236.65K
31.22%
+72.09K
2023Q3
78
164.55K
39.28%
-2.06K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
50.67K
0.89%
+23.15K
+84.08%
Sep 30, 2025
Calise (Chris)
312.69K
5.5%
--
--
Dec 18, 2025
Mehalick (David)
130.07K
2.29%
--
--
Dec 18, 2025
Armistice Capital LLC
94.77K
1.67%
+94.77K
--
Sep 30, 2024
Sheehy (Christine Elise)
50.53K
0.89%
--
--
Dec 18, 2025
Yerace (Daniel Alexander)
45.53K
0.8%
--
--
Dec 18, 2025
Geode Capital Management, L.L.C.
37.38K
0.66%
+17.10K
+84.30%
Sep 30, 2025
State Street Investment Management (US)
19.87K
0.35%
+19.87K
--
Sep 30, 2025
Renaissance Technologies LLC
18.50K
0.33%
+18.50K
--
Sep 30, 2025
Yorkville Advisors Global, LP.
8.00K
0.14%
-44.72K
-84.83%
Sep 30, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Dec 27, 2024
Merger
20→1
Dec 27, 2024
Merger
20→1
Dec 27, 2024
Merger
20→1
Dec 27, 2024
Merger
20→1
Fecha
Fecha ex-dividendo
Tipo
Relación
Dec 27, 2024
Merger
20→1
Dec 27, 2024
Merger
20→1
Dec 27, 2024
Merger
20→1
Dec 27, 2024
Merger
20→1
